“atlas-venture” Archives

in
Entry Author Date Location
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases 08/26/20 Boston
Kymera Therapeutics Unveils IPO Pitch for Protein Degradation 07/31/20 Boston
Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More 06/05/20 National
Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq 05/22/20 National
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic 05/21/20 Boston
Xilio Unveils New Name, $100M to Bring Targeted Cancer Drugs to Clinic 03/02/20 Boston
Quench Bio Springs From Atlas With $50M for a New Take on Inflammation 01/27/20 Boston
Generation Bio Pockets $110M for Next Wave of Gene Therapy, IPO Plans 01/13/20 Boston
Triplet Therapeutics Unveils $59M to Try Hairpin Fix for Huntington’s 12/17/19 Boston
IFM Lands $55.5M to Launch NewCo Quattro and Discovery Incubator 12/02/19 Boston
Arkuda Unveils $44M and a Protein Restoration Approach to Dementia 11/07/19 Boston
Venture Investors Bets on Healthcare, and Milwaukee, With $75M Fund 10/28/19 Wisconsin
Bio Roundup: Gottlieb’s Goodbye, AACR Recap, Migraine Drug Fight & More 04/05/19 National
Dyne Therapeutics Emerges With $50M to Take On Rare Muscle Disease 04/03/19 Boston
Flagship Reloads With $824M For Latest Growth Capital Fund 03/20/19 Boston
The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski 03/11/19 National
Moving HQ to Boston, AtScale CEO Chris Lynch Talks VCs, Tech Scene 01/28/19 Boston
Atlas Venture Bags $250M For New Growth Capital Fund 01/02/19 Boston
Kymera Adds $65M in New Funding and Eyes First Clinical Test 11/13/18 Boston
Akrevia Launches with $30M for Next-Gen Cancer Immunotherapy 09/27/18 Boston
Fresh Off Bristol Buyout, IFM Backers Raise $31M to Plot a Second Strike 07/19/18 Boston
With $45M, HotSpot Takes Drug Research to New Biological Real Estate 07/17/18 Boston
Ex-Accomplice Partner Lynch Returns to Corner Office with AtScale 06/26/18 Boston
Akero Closes $65M Financing to Back Liver Drug Licensed from Amgen 06/25/18 Boston
Nimbus Nabs $65M to Advance In-House Drug Discoveries to the Clinic 06/05/18 Boston
Accent Therapeutics Debuts With $40M To Target RNA Modification 05/18/18 Boston
Rubius Rolls Up Another $100M As Bio Funding Frenzy Continues 03/01/18 Boston
Avrobio Raises $60M for Fabry Disease Gene Therapy, Rest of Pipeline 02/01/18 Boston
Accomplice Reloads With $205M Fund After Makeover 01/18/18 Boston
Gene Therapy 2.0: New Startups Aim to Fine-Tune Gene Delivery and Control 01/04/18 Boston
Page 1 of 21 next page »